Thanks the Administration for working with AAM and industry
WASHINGTON (April 2, 2026) — The Association for Accessible Medicines today applauded the proclamation signed by President Trump announcing the final results of a Section 232 investigation into possible tariffs and trade issues concerning pharmaceuticals. The investigation started in April of last year.
“The generics and biosimilars industry applaud the Administration for recognizing the unique aspects of our industry’s supply chain and exempting generic and biosimilar medicines from tariffs under this 232 investigation,” said John Murphy III, President and CEO of the Association for Accessible Medicines. “We are especially grateful to the Administration for working with AAM and the Biosimilars Council along with our member companies over the last year to discuss the unique aspects of the generics ecosystem and explore ways to strengthen both the resiliency of the overall supply chain as well as enhance the ability of the industry to grow here in the U.S.
“There was a clear appreciation and understanding of the savings and access provided to American patients, as well as the potential harms and unintended consequences associated with further burdening the economics of our industry in the U.S.
“This decision will help enhance the generic medicines supply chain, which is critical to patient health and U.S. healthcare and national security interests. We look forward to continuing to work with the Administration, Congress, and key stakeholders on reforms that prioritize patients, enhance the industry’s U.S. footprint, strengthen our national security, and ultimately increase access for American patients to a reliable lower-cost medicines ecosystem.”
AAM Release on Start of 232 Investigation
AAM Release on February 2025 Tariffs
U.S. Generic & Biosimilar Medicines Savings Report
Media contact: media@accessiblemeds.org
About AAM
The Association for Accessible Medicines, your generics and biosimilars industry, is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. AAM represents the manufacturers of finished generic pharmaceuticals and biosimilars, manufacturers of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 12 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines, works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is the leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, government affairs, legal affairs, and regulatory policy. More information is available at www.biosimilarscouncil.org.
